Es gibt da auch noch ein 10Q-Filing. Solltest Du Dir mal bei Edgar Online ansehen.
Hast Du schon die Quartalszahlen??
Hier noch eine News zu den Ergebnissen von Ende Oktober:
Matrix Pharmaceutical Reports Financial Results for Third Quarter 2001 Development Plans for Tezacitabine on Track
FREMONT, Calif., Oct 30, 2001 /PRNewswire via COMTEX/ -- Matrix Pharmaceutical,
Inc. (Nasdaq: MATX) today reported financial results for the three months ended
September 30, 2001. The Company reported a net loss for the third quarter of
2001 of $7,838,000, or $0.30 per share, on a basic and diluted basis compared to
a net loss of $5,299,000, or $0.21 per share, in the third quarter of 2000.
Matrix ended the third quarter of 2001 with $33,026,000 in cash, cash
equivalents and marketable securities.
Third quarter results were in line with expected expenditures associated with
earlier plans for the market launch of IntraDose(R) (cisplatin/epinephrine)
Injectable Gel. However, Matrix halted those plans, and announced in October a
restructuring program in order to focus the Company on research and development
efforts.
"Matrix is moving forward rapidly with its plans to focus on the development of
tezacitabine and to pursue registration of IntraDose in Europe," said Michael D.
Casey, Chairman, President and Chief Executive Officer. "Our development plans
for tezacitabine are on track and we expect to start a new Phase II study in
leukemia in the first quarter of 2002."
In early October 2001 Matrix announced plans to submit an application for the
approval of IntraDose for head and neck cancer to the European Medicines
Evaluation Agency (EMEA) in the fourth quarter of 2001. Matrix also announced
development plans for tezacitabine, a novel chemotherapy candidate, that Matrix
believes has broad therapeutic potential.
In an effort to provide adequate resources for a newly-focused organization,
Matrix announced on October 10, 2001 a restructuring program that included the
possible sale of its manufacturing business unit and downsizing its current
workforce. Matrix reduced its number of employees by about 40% (excluding those
involved in its manufacturing unit in San Diego).
Total revenues from Matrix Contract Services, (MCS), increased to $773,000 in
the third quarter of 2001 compared to $620,000 in the third quarter of 2000.
Total Matrix costs and expenses were $8,860,000 during the third quarter of 2001
compared to $6,829,000 during the same quarter of 2000. Matrix research and
development expenses increased in the third quarter of 2001 to $5,499,000 from
$4,692,000 in the third quarter of 2000. The increase was primarily due to
higher regulatory consulting expenses, recruiting costs and San Diego plant
operating costs. This was partially offset by higher New Drug Application (NDA)
preparation costs in the third quarter of 2000.
General and administrative expenses increased to $2,921,000 for the third
quarter of 2001 from $1,731,000 in the third quarter of 2000, principally due to
higher market preparation expenses for IntraDose, consulting expenses and
recruiting costs. Net interest and other income declined to $249,000 in the
third quarter of 2001 from $910,000 in the year-earlier quarter due to declining
cash balances and lower interest rates on investments.
For the first nine months of 2001 the Company recorded a loss of $22,498,000 or
$0.86 per share compared with a loss of $16,529,000, or $0.70 per share for the
same period of 2000. Total MCS revenues increased to $1,488,000 from $1,052,000
in the year-earlier period. Total Matrix costs and expenses increased in the
first nine months of 2001 to $25,223,000 from $19,426,000 for the year-earlier
period, due to increased market preparation expenses associated with IntraDose,
higher personnel costs to support clinical programs, increased regulatory
consulting costs, and higher operating costs at our San Diego facility.
